Irmgard Irminger-Finger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Irmgard Irminger-Finger has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Atzori
Clinical Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy
2 shared publications Alvin M. Malkinson
Department of Pharmacological Science, University of Colorado Denver, Aurora, CO
1 shared publicationAndrea Bianco
Chair of Respiratory Diseases, Department of Health Sciences, University of Molise, Campobasso, Italy
1 shared publicationD Kuester
Institute of Pathology, Otto-von-Guericke University, Magdeburg, Germany
1 shared publicationG Casula
Department of Surgery, University of Cagliari, Cagliari, Italy
1 shared publicationGeoffrey J. Laurent
Centre for Respiratory Research, University College London, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 19 July 2012
- Published by Springer Nature in British Journal of Cancer
- Vol. 107 (4) , 675-683
Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome
Background: Colon cancer predisposition is associated with mutations in BRCA1. BRCA1 protein stability depends on binding to BARD1. In different cancers, expression of differentially spliced BARD1 isoforms is correlated with poor prognosis and decreased patient survival. We therefore suspected a role of BARD1 isoforms in colon cancer. Methods: We performed immunohistochemistry in 168 colorectal cancers, using four antibodies directed against differentially expressed regions of BARD1. We determined structure and relative expression of BARD1 mRNA isoforms in 40 tumour and paired normal peri-tumour tissues. BARD1 expression was correlated with clinical outcome. Results: BARD1 isoforms were expressed in 98% of cases and not correlated with BRCA1. BARD1 mRNA isoforms were upregulated in all tumours as compared with paired normal peri-tumour tissues. Non-correlated expression and localisation of different epitopes suggested insignificant expression of full-length (FL) BARD1. Expression of N- and C-terminal epitopes correlated with increased survival, but expression of epitopes mapping to the middle of BARD1 correlated with decreased survival. Middle epitopes are present in oncogenic BARD1 isoforms, which have pro-proliferative functions. Correlated upregulation of only N- and C-terminal epitopes reflects the expression of isoforms BARD1δ and BARD1ϕ. Conclusion: Our results suggest that BARD1 isoforms, but not FL BARD1, are expressed in colon cancer and affect its progression and clinical outcome.
- 19 July 2012
- Published by Springer Nature in British Journal of Cancer
- Vol. 107 (4) , 675-683
Open AccessExpression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome
Background: Colon cancer predisposition is associated with mutations in BRCA1. BRCA1 protein stability depends on binding to BARD1. In different cancers, expression of differentially spliced BARD1 isoforms is correlated with poor prognosis and decreased patient survival. We therefore suspected a role of BARD1 isoforms in colon cancer. Methods: We performed immunohistochemistry in 168 colorectal cancers, using four antibodies directed against differentially expressed regions of BARD1. We determined structure and relative expression of BARD1 mRNA isoforms in 40 tumour and paired normal peri-tumour tissues. BARD1 expression was correlated with clinical outcome. Results: BARD1 isoforms were expressed in 98% of cases and not correlated with BRCA1. BARD1 mRNA isoforms were upregulated in all tumours as compared with paired normal peri-tumour tissues. Non-correlated expression and localisation of different epitopes suggested insignificant expression of full-length (FL) BARD1. Expression of N- and C-terminal epitopes correlated with increased survival, but expression of epitopes mapping to the middle of BARD1 correlated with decreased survival. Middle epitopes are present in oncogenic BARD1 isoforms, which have pro-proliferative functions. Correlated upregulation of only N- and C-terminal epitopes reflects the expression of isoforms BARD1δ and BARD1ϕ. Conclusion: Our results suggest that BARD1 isoforms, but not FL BARD1, are expressed in colon cancer and affect its progression and clinical outcome.
- Open Access
- 3 August 2011
- Published by Wiley in International Journal of Cancer
- Vol. 131 (1) , 83-94
BARD1: An independent predictor of survival in non‐small cell lung cancer
BRCA1 mRNA overexpression is correlated with poor survival in NSCLC. However, BRCA1 functions depend on the interaction with BARD1 for its stability, nuclear localization and ubiquitin ligase activity. Expression of alternatively spliced BARD1 isoforms that lack the BRCA1‐interaction domain was found upregulated and correlated with poor prognosis in breast and ovarian cancer. These BARD1 isoforms are essential for proliferation of cancer cells in vitro. We investigated whether BARD1 isoforms are expressed in NSCLC. While in lung tissues from healthy controls BARD1 expression was undetectable on the mRNA level and protein level, we found two novel isoforms in addition to previously identified mRNAs expressed in all NSCLC samples tested. Furthermore, the pattern of BARD1 isoform expression was similar in tumor and morphologically normal peri‐tumor tissues, and only one novel isoform π was specifically upregulated in tumors. Immunohistochemistry revealed that all 100 NSCLC cases tested expressed isoform‐specific BARD1 epitopes, while BARD1 expression was undetectable in biopsies from healthy controls. Statistical analysis showed that the expression of epitopes PVC and WFS, present on isoform π, or epitope WFS alone, expressed on isoforms π, κ and β, were significantly correlated with decreased patient survival. These findings were corroborated in a mouse model of chemically induced lung cancer. Immunostaining of mouse tumors showed that BARD1 epitopes PVC and WFS were specifically upregulated in invasive, but not in confined lung tumors. Thus, BARD1 isoforms might be involved in tumor initiation and invasive progression and might represent a novel prognostic marker for NSCLC.
- 3 August 2011
- Published by Wiley in International Journal of Cancer
- Vol. 131 (1) , 83-94
Open AccessBARD1: An independent predictor of survival in non‐small cell lung cancer
BRCA1 mRNA overexpression is correlated with poor survival in NSCLC. However, BRCA1 functions depend on the interaction with BARD1 for its stability, nuclear localization and ubiquitin ligase activity. Expression of alternatively spliced BARD1 isoforms that lack the BRCA1‐interaction domain was found upregulated and correlated with poor prognosis in breast and ovarian cancer. These BARD1 isoforms are essential for proliferation of cancer cells in vitro. We investigated whether BARD1 isoforms are expressed in NSCLC. While in lung tissues from healthy controls BARD1 expression was undetectable on the mRNA level and protein level, we found two novel isoforms in addition to previously identified mRNAs expressed in all NSCLC samples tested. Furthermore, the pattern of BARD1 isoform expression was similar in tumor and morphologically normal peri‐tumor tissues, and only one novel isoform π was specifically upregulated in tumors. Immunohistochemistry revealed that all 100 NSCLC cases tested expressed isoform‐specific BARD1 epitopes, while BARD1 expression was undetectable in biopsies from healthy controls. Statistical analysis showed that the expression of epitopes PVC and WFS, present on isoform π, or epitope WFS alone, expressed on isoforms π, κ and β, were significantly correlated with decreased patient survival. These findings were corroborated in a mouse model of chemically induced lung cancer. Immunostaining of mouse tumors showed that BARD1 epitopes PVC and WFS were specifically upregulated in invasive, but not in confined lung tumors. Thus, BARD1 isoforms might be involved in tumor initiation and invasive progression and might represent a novel prognostic marker for NSCLC.
- 1 May 2010
- Published by Elsevier in Gynecologic Oncology
- Vol. 117 (2) , 211-215
BARD1, a possible biomarker for breast and ovarian cancer
- 1 May 2010
- Published by Elsevier in Gynecologic Oncology
- Vol. 117 (2) , 211-215
BARD1, a possible biomarker for breast and ovarian cancer
- 4 December 2009
- Published by Springer Nature
- p. 3-19
Basic Science of Breast Cancer in Older Patients
- 1 January 2008
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 40 (10) , 1979-1983
Preeclampsia: A danger growing in disguise
- 1 January 2008
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 40 (10) , 1979-1983
Preeclampsia: A danger growing in disguise